1. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013; 19:837–849.
Article
2. Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimägi L, Tefanova V. Predictors of treatment response in patients with hepatitis C 1b genotype. Cent Euro J Med. 2013; 8:822–829.
Article
3. Morozov VA, Lagaye S. Hepatitis C virus: morphogenesis, infection and therapy. World J Hepatol. 2018; 10:186–212.
Article
4. Pol S, Parlati L. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in “special populations”. Liver Int. 2018; 38:Suppl 1. 28–33.
Article
5. Huang D, Koh C, Feurtado JA, Tsang EW, Cutler AJ. MicroRNAs and their putative targets in Brassica napus seed maturation. BMC Genomics. 2013; 14:140.
Article
6. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011; 3:83–92.
7. Piedade D, Azevedo-Pereira JM. MicroRNAs, HIV and HCV: a complex relation towards pathology. Rev Med Virol. 2016; 26:197–215.
Article
8. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005; 309:1577–1581.
Article
9. Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology. 2010; 398:57–67.
Article
10. Li S, Duan X, Li Y, Liu B, McGilvray I, Chen L. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat. 2014; 21:121–128.
Article
11. Lin Y, Jin Y, Xu T, Zhou S, Cui M. MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer. Am J Transl Res. 2017; 9:466–477.
12. Yao J, Zhang P, Li J, Xu W. MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1. Oncol Lett. 2017; 14:1097–1104.
Article
13. Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, et al. MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. Oncogenesis. 2017; 6:399.
Article
14. Zang Y, Wang T, Pan J, Gao F. miR-215 promotes cell migration and invasion of gastric cancer cell lines by targeting FOXO1. Neoplasma. 2017; 64:579–587.
Article
15. Wei Y, Sun J, Li X. MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in highgrade glioma. Biotechnol Lett. 2017; 39:197–205.
Article
16. Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun. 2011; 412:92–97.
Article
17. Ozato K, Shin DM, Chang TH, Morse HC 3rd. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008; 8:849–860.
Article
18. Watanabe M, Hatakeyama S. TRIM proteins and diseases. J Biochem. 2017; 161:135–144.
Article
19. Yap MW, Stoye JP. TRIM proteins and the innate immune response to viruses. Adv Exp Med Biol. 2012; 770:93–104.
Article
20. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 2008; 4:e1000007.
Article
21. Gao B, Duan Z, Xu W, Xiong S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology. 2009; 50:424–433.
Article
22. Yang C, Zhao X, Sun D, Yang L, Chong C, Pan Y, et al. Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol. 2016; 13:94–102.
Article
23. He Y, Weng L, Li R, Li L, Toyoda T, Zhong J. The N-terminal helix α(0) of hepatitis C virus NS3 protein dictates the subcellular localization and stability of NS3/NS4A complex. Virology. 2012; 422:214–223.
Article
24. Yu S, Gao B, Duan Z, Xu W, Xiong S. Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-κB activator. Biochem Biophys Res Commun. 2011; 410:247–251.
Article
25. Waldron PR, Holodniy M. MicroRNA and hepatitis C virus—challenges in investigation and translation: a review of the literature. Diagn Microbiol Infect Dis. 2014; 80:1–12.
Article
26. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007; 449:919–922.
Article
27. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, et al. A cellular microRNA mediates antiviral defense in human cells. Science. 2005; 308:557–560.
Article
28. Wang C, Chen Q, Li S, Li S, Zhao Z, Gao H, et al. Dual inhibition of PCDH9 expression by miR-215-5p up-regulation in gliomas. Oncotarget. 2017; 8:10287–10297.
Article
29. Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R, et al. miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer. Oncol Lett. 2015; 10:1985–1992.
Article
30. Mamdouh S, Khorshed F, Aboushousha T, Hamdy H, Diab A, Seleem M, et al. Evaluation of mir-224, mir-215 and mir-143 as serum biomarkers for HCV associated hepatocellular carcinoma. Asian Pac J Cancer Prev. 2017; 18:3167–3171.
31. Ali SA, Alahmady ZZ, Yamany HA, Abul-Fotouh AM. Serum expression levels of miR-141 and miR-215 for differentiation between liver cirrhosis, chronic hepatitis C and hepatocellular carcinoma patients. Microbiol Res J Int. 2017; 20:1–12.
Article
32. Tissot C, Mechti N. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem. 1995; 270:14891–14898.
Article
33. Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol. 2011; 85:208–216.
Article
34. Di Pietro A, Kajaste-Rudnitski A, Oteiza A, Nicora L, Towers GJ, Mechti N, et al. TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol. 2013; 87:4523–4533.
Article
35. Ng TI, Mo H, Pilot-Matias T, He Y, Koev G, Krishnan P, et al. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology. 2007; 45:1413–1421.
Article
36. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A. 2007; 104:12884–12889.
Article
37. Zhang L, Alter HJ, Wang H, Jia S, Wang E, Marincola FM, et al. The modulation of hepatitis C virus 1a replication by PKR is dependent on NF-kB mediated interferon beta response in Huh7.5.1 cells. Virology. 2013; 438:28–36.
Article